This study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) live longer without their cancer growing. Participants must have already tried and failed an EGFR-targ…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:20 UTC